CEO Today Global Awards

www.ceotodaymagazine.com 18 CEO Today Global Awards 2019 belgium JOHN TCHELINGERIAN President & CEO of Promethera Biosciences www.promethera.com ABOUT JOHN TCHELINGERIAN, PHD Dr John Tchelingerian is a serial entrepreneur combining strong scientific, business, managerial and deal making experience. He co-founded and managed several biotech companies including Neurotech, Key-Obs, Diatos, TcLand Expression, Key Neurosciences and Melkin Pharmaceuticals and raised over $100 million (€81 million) from VCs and private equity sources in Europe, the US and Japan to fund these businesses. He has also closed several biotech and pharma partnering deals. Under his leadership, four drugs were developed from the research stage up to clinical phase IIb/III as well as DaunoXome repositioned and relaunched in a rare cancer indication both in the USA and the EU, based on phase III clinical trials. John co-founded Paris-based Silver Ocean Ventures, a strategic advisory and corporate finance firm, in 2009. It services the global life sciences industry regarding primarily in corporate finance, strategic business transactions and active board and leadership roles. John has been responsible for Silver Ocean Ventures closing several international financing rounds and M&A transactions with a total value of over €50 million. As a scientist, John is inventor in several patents in the field of cell therapy and drug delivery. He received his PhD in Neurosciences from Pierre et Marie Curie University in Paris, France. He is fluent in five languages. Since joining Promethera Biosciences as the Chief Executive Officer in September 2015, Promethera has been transformed into a global leader in regenerative medicine focused on severe and devastating liver diseases. Under his leadership, the company became a pioneer in bringing cell-based therapies to a segment of the healthcare market - severe diseases of the liver - that had until then not benefitted from these novel approaches. Innovation in the space is highly needed, since the demand for liver transplantation will rise to a level that can no longer be met by society if the incident rates of diseases like NASH and ACLF and the disease progression per patient continue to develop unchecked. In 2016, Promethera acquired access to a dedicated organ and tissue processing unit, product manufacturing expertise, and a world- class liver sourcing with the largest existing Organ Procurement Organizations (OPO) network in the U.S. In 2017, Promethera had signed a strategic collaboration with Shibuya Corporation to establish a high-throughput, commercial- scale and clinical-grade cell therapy and regenerative medicine manufacturing platform. The collaboration will act as a cornerstone to optimize and expand the manufacturing capabilities. To further strengthen its pipeline, mitigate risk and create internal as well as external combination therapy opportunities, Promethera acquired Swiss biopharmaceutical company Baliopharm focused on the development of targeted biological therapies for immune mediated inflammatory diseases and cancer. Geographically, Promethera has established the group with a global footprint early on. The expansion into the USA provided Promethera with high-quality manufacturing capabilities and infrastructure as well as access to a stable source of donated livers. The expansion to Japan and Asia enables Promethera to benefit from the very stem cell-friendly regulatory environment in these markets, which suffer from a historically and culturally embedded lack of organ donations. Overall, Promethera is following a long-term strategy to establish the firm as a leading biopharmaceutical company with deep roots in cell therapy and a global reach.